Ray Dalio's EW Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 180,307 shares of Edwards Lifesciences Corporation (EW) worth $14.02 M, representing 0.05% of the portfolio. First purchased in 2013-Q3, this long-term strategic position has been held for 49 quarters.
Based on 13F filings since 2013, Ray Dalio has maintained a long-term strategic position in EW, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2025, adding 382,402 shares. Largest reduction occurred in Q1 2024, reducing 417,561 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's Edwards Lifesciences Corporation (EW) Holding Value Over Time
Track share changes against reported price movement
Quarterly Edwards Lifesciences Corporation (EW) Trades by Ray Dalio
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2013 | +154,170 | New Buy | 154,170 | $11.60 |
| Q4 2013 | -154,170 | Sold Out | 154,170 | $0.00 |
| Q2 2015 | +191,688 | New Buy | 191,688 | $23.74 |
| Q3 2015 | -191,688 | Sold Out | 191,688 | $0.00 |
| Q1 2016 | +56,400 | New Buy | 56,400 | $29.40 |
| Q2 2016 | +45,000 | Add 79.79% | 101,400 | $33.24 |
| Q3 2016 | +33,795 | Add 33.33% | 135,195 | $40.19 |
| Q4 2016 | -135,195 | Sold Out | 135,195 | $0.00 |
| Q1 2017 | +136,245 | New Buy | 136,245 | $31.36 |
| Q2 2017 | -14,163 | Reduce 10.40% | 122,082 | $39.42 |
| Q3 2017 | +237,159 | Add 194.26% | 359,241 | $36.44 |
| Q4 2017 | -260,745 | Reduce 72.58% | 98,496 | $37.56 |
| Q1 2018 | -98,496 | Sold Out | 98,496 | $0.00 |
| Q3 2018 | +28,770 | New Buy | 28,770 | $58.05 |
| Q4 2018 | -28,770 | Sold Out | 28,770 | $0.00 |
| Q2 2019 | +22,401 | New Buy | 22,401 | $61.56 |
| Q3 2019 | +6,342 | Add 28.31% | 28,743 | $73.30 |
| Q4 2019 | -28,743 | Sold Out | 28,743 | $0.00 |
| Q1 2020 | +7,386 | New Buy | 7,386 | $62.82 |
| Q2 2020 | -7,386 | Sold Out | 7,386 | $0.00 |
| Q3 2020 | +143,657 | New Buy | 143,657 | $79.82 |
| Q4 2020 | +169,585 | Add 118.05% | 313,242 | $91.23 |
| Q1 2021 | +76,657 | Add 24.47% | 389,899 | $83.64 |
| Q2 2021 | +307,385 | Add 78.84% | 697,284 | $103.57 |
| Q3 2021 | -7,619 | Reduce 1.09% | 689,665 | $113.21 |
| Q4 2021 | +117,220 | Add 17.00% | 806,885 | $129.55 |
| Q1 2022 | +328,371 | Add 40.70% | 1.14 M | $117.72 |
| Q2 2022 | -139,899 | Reduce 12.32% | 995,357 | $95.09 |
| Q3 2022 | +135,355 | Add 13.60% | 1.13 M | $82.63 |
| Q4 2022 | -224,153 | Reduce 19.82% | 906,559 | $74.61 |
| Q1 2023 | +36,667 | Add 4.04% | 943,226 | $82.73 |
| Q2 2023 | -160,942 | Reduce 17.06% | 782,284 | $94.33 |
| Q3 2023 | +273,312 | Add 34.94% | 1.06 M | $69.28 |
| Q4 2023 | -152,368 | Reduce 14.43% | 903,228 | $76.25 |
| Q1 2024 | -417,561 | Reduce 46.23% | 485,667 | $95.56 |
| Q2 2024 | +34,145 | Add 7.03% | 519,812 | $92.37 |
| Q3 2024 | -354,361 | Reduce 68.17% | 165,451 | $65.99 |
| Q4 2024 | -57,166 | Reduce 34.55% | 108,285 | $74.03 |
| Q1 2025 | -45,763 | Reduce 42.26% | 62,522 | $72.48 |
| Q2 2025 | +382,402 | Add 611.63% | 444,924 | $78.21 |
| Q3 2025 | -264,617 | Reduce 59.47% | 180,307 | $77.77 |
Ray Dalio's Edwards Lifesciences Corporation Investment FAQs
Ray Dalio first purchased Edwards Lifesciences Corporation (EW) in Q3 2013, acquiring 154,170 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held Edwards Lifesciences Corporation (EW) for 49 quarters since Q3 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio's largest addition to Edwards Lifesciences Corporation (EW) was in Q2 2025, adding 444,924 shares worth $34.8 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 180,307 shares of Edwards Lifesciences Corporation (EW), valued at approximately $14.02 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Edwards Lifesciences Corporation (EW) represents approximately 0.05% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio's peak holding in Edwards Lifesciences Corporation (EW) was 1,135,256 shares, as reported at the end of Q1 2022. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.